CXCL16 and neoplasm: Furthermore, simvastatin increased CXCL16 expression in LSECs, while CXCL16 remains a ligand for the CXCR6 receptor expressed by NK cells, causing the recruitment of natural killer (NK) cells and leading to an anti-tumor immune-mediating response.